From $10M to $225M+

The Flash Report

11 Mar 2026 — 1 min read

RAD Intel’s current Reg A+ round remains open at $0.85 per share, though that price is scheduled to change.

The company has grown from a $10M valuation at merger to $225M+, raised $60M+, and is backed by multiple Fidelity funds. It was selected by the Adobe Design Fund and has secured recurring seven-figure enterprise contracts across Fortune 1000 brands.

Sales contracts doubled from 2024 to 2025*, and the NASDAQ ticker has been reserved: $RADI.

For investors evaluating entry, this may be the final window at the current tier.

Review the Offering Before the Price Changes

This is a paid advertisement for RAD Intel made pursuant to Regulation A+ offering and involves risk, including the possible loss of principal. The valuation is set by the Company and there is currently no public market for the Company's Common Stock. Nasdaq ticker “$RADI” has been reserved by RAD Intel and any potential listing is subject to future regulatory approval and market conditions. Brand references reflect factual platform use, not endorsement. Investor references reflect factual individual or institutional participation and do not imply endorsement or sponsorship by the referenced companies. Some media placements are earned organically, while others may be paid sponsorships or promotional placements. Please read the offering circular and related risks at invest.$RADIntel.ai.

The Biggest Unsolved Problem in Medicine?

Today, over half a billion people battle osteoarthritis. Each year, they spend $240B trying to halt the destruction of joint cartilage. But no cure exists on the market. Not for lack of trying, either. Big Pharma’s spent billions failing. Thankfully, Cytonics may have cracked the code. They discovered the

What if David and Goliath teamed up instead?

That’s what’s currently playing out in the foodservice industry, where industry goliaths Sodexo, Aramark, and Compass Group all partnered with foodtech startup Automated Retail Technologies. Why did they choose ART? With more than 150,000 venues managed by that trio alone, staffing overnight operations is costly and complicated.

The Key to This $500B Market Is in Your Bloodstream

Every year, $240B is spent on treating the symptoms of osteoarthritis, a disease that leads to joint degradation and, eventually, immobility. With 500M people afflicted, its total addressable market is worth over $500B. But not a single therapy has been able to actually stop it. The answer, it turns out,

Superhuman' Pre-IPO Stock Trading Under $1

Have you heard about this sub $1 Pre-IPO company that is making people "Superhumans"? It's all thanks to their new product called Visor. And it's very similar to Jarvis from the movie Iron Man. Investors are calling this a 'massive breakthrough'. But

Read more

The Biggest Unsolved Problem in Medicine?

What if David and Goliath teamed up instead?

The Key to This $500B Market Is in Your Bloodstream

Superhuman' Pre-IPO Stock Trading Under $1